#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	3578	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2599	402.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1551	1551	C	483	C,A	438,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5872	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4068	431.6	0	.	n	.	0	T695C	SNP	695	695	T	1359	1359	C	460	C	408	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5872	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4068	431.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	2001	2001	A	525	A	480	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5872	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4068	431.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2635	2635	C	520	C,T,A	469,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5872	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4068	431.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2709	2709	A	548	A,C	488,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	5872	23S	2890	2890	99.9	23S.l15.c4.ctg.1	4068	431.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3261	3261	C	527	C,A	465,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	542	folP	852	852	100.0	folP.l15.c4.ctg.1	1986	81.2	1	SNP	p	R228S	1	.	.	682	684	AGC	1171	1173	AGC	113;114;114	A,G;G;C	98,1;102;98	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1132	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4020	84.3	1	SNP	p	S91F	0	.	.	271	273	TCC	923	925	TCC	88;89;89	T;C;C	77;80;81	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1132	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4020	84.3	1	SNP	p	D95G	0	.	.	283	285	GAC	935	937	GAC	87;89;90	G;A;C	79;80;80	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1132	gyrA	2751	2751	99.85	gyrA.l6.c4.ctg.1	4020	84.3	1	SNP	p	D95N	0	.	.	283	285	GAC	935	937	GAC	87;89;90	G;A;C	79;80;80	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	M16I	NONSYN	46	48	ATG	695	697	ATT	80;80;79	A;T;T	71;74;69	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	D40A	NONSYN	118	120	GAC	767	769	GCC	72;74;74	G;C;C	64;66;64	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	R44H	NONSYN	130	132	CGC	779	781	CAC	72;72;72	C;A;C	62;63;64	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	I73M	NONSYN	217	219	ATC	866	868	ATG	58;58;58	A;T;G	54;51;52	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	A74S	NONSYN	220	222	GCG	869	871	TCG	58;58;58	T;C;G	53;55;55	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	Q75K	NONSYN	223	225	CAA	872	874	AAA	59;59;59	A;A;A	57;59;57	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	A77T	NONSYN	229	231	GCC	878	880	ACG	60;60;60	A;C;G	58;57;51	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	.	MULTIPLE	233	234	CA	882	884	AAA	61;61;61	A;A;A	60;58;57	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	D79N	NONSYN	235	237	GAT	887	889	AAT	61;61;61	A;A;T	58;58;55	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	G83Q	NONSYN	247	249	GGG	899	901	CAA	61;61;61	C;A;A	56;58;58	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	H90R	NONSYN	268	270	CAC	920	922	CGT	63;63;63	C;G;T	58;57;59	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	N110S	NONSYN	328	330	AAC	980	982	AGC	61;61;61	A;G;C	57;58;56	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	V143F	NONSYN	427	429	GTT	1079	1081	TTT	47;47;47	T;T;T	41;40;40	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	A154S	NONSYN	460	462	GCT	1112	1114	TCG	36;36;36	T;C;G	32;33;32	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	D155G	NONSYN	463	465	GAC	1115	1117	GGT	36;35;35	G,T;G;T	31,1;32;31	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	T161M	NONSYN	481	483	ACG	1133	1135	ATG	34;34;34	A;T;G	31;31;31	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	T169M	NONSYN	505	507	ACG	1157	1159	ATG	34;34;34	A;T;G	30;33;32	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	F178L	NONSYN	532	534	TTC	1184	1186	CTC	31;31;31	C;T;C	29;29;29	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	S183N	NONSYN	547	549	AGT	1199	1201	AAT	31;31;31	A;A;T	28;28;28	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	G195E	NONSYN	583	585	GGG	1235	1237	GAA	30;30;29	G;A;A	26;25;25	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	0	.	p	.	0	C206Q	NONSYN	616	618	TGC	1268	1270	CAG	22;22;22	C;A;G	22;22;22	.	.
mtrR.WHO_Z_01455	mtrR.WHO_Z_01455	1	1	539	194	mtrR	633	633	91.19	mtrR.l15.c4.ctg.1	1697	34.3	1	SNP	p	G45D	0	.	.	133	135	GGC	782	784	GGC	72;72;73	G;G;C,A	63;63;64,1	mtrR.WHO_Z_01455:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1358	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3680	110.5	1	SNP	p	D86N	0	.	.	256	258	GAC	919	921	GAC	129;128;128	G;A;C	114;111;118	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1358	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3680	110.5	1	SNP	p	S87I	0	.	.	259	261	AGT	922	924	AGT	128;128;127	A;G;T	111;120;115	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1358	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3680	110.5	1	SNP	p	S87W	0	.	.	259	261	AGT	922	924	AGT	128;128;127	A;G;T	111;120;115	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1358	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3680	110.5	1	SNP	p	S87R	0	.	.	259	261	AGT	922	924	AGT	128;128;127	A;G;T	111;120;115	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1358	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3680	110.5	1	SNP	p	S88P	0	.	.	262	264	TCC	925	927	TCC	126;126;127	T;C;C,G	116;112;118,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1114	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3058	108.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1714	1716	GGC	143;140;140	G;G;C	130;124;128	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	934	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2962	94.3	1	SNP	p	A311V	0	.	.	931	933	GCA	1548	1550	GCA	130;130;131	G;C;A,C	122;120;121,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	934	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2962	94.3	1	SNP	p	I312M	0	.	.	934	936	ATC	1551	1553	ATC	131;131;132	A;T,C;C	118;118,1;118	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	934	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2962	94.3	1	SNP	p	V316P	0	.	.	946	948	GTG	1563	1565	GTG	129;129;131	G,A;T,C;G,C	119,1;119,1;117,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	934	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2962	94.3	1	SNP	p	V316T	0	.	.	946	948	GTG	1563	1565	GTG	129;129;131	G,A;T,C;G,C	119,1;119,1;117,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	934	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2962	94.3	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2067	2069	ACC	99;100;99	A,C;C;C	93,1;94;95	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	934	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2962	94.3	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2121	2123	GCG	109;109;109	G,T;C,A;G	94,1;75,1;86	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	934	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2962	94.3	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2121	2123	GCG	109;109;109	G,T;C,A;G	94,1;75,1;86	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	934	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2962	94.3	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2244	2246	GGC	107;107;107	G,C;G;C	92,1;94;97	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	934	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2962	94.3	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2253	2255	GGC	105;105;106	G,C;G;C,T	91,1;91;93,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	934	penA	1749	1749	100.0	penA.l6.c17.ctg.1	2962	94.3	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2271	2273	CCG	109;109;110	C,G;C;G	89,1;97;91	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1264	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3640	103.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	646	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2413	80.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	965	965	C	117	C,G	109,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	120	porB1a	984	296	91.0	porB1a.l15.c4.ctg.1	1472	23.7	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1201	1203	AAT	19;19;19	A;A;T	15;15;14	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	120	porB1a	984	296	91.0	porB1a.l15.c4.ctg.1	1472	23.7	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1204	1206	AAT	19;19;19	A,T;A;T	15,1;15;15	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	120	porB1a	984	296	91.0	porB1a.l15.c4.ctg.1	1472	23.7	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1228	1230	GCA	14;14;14	G;C;A	14;14;13	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	120	porB1a	984	296	91.0	porB1a.l15.c4.ctg.1	1472	23.7	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1251	1253	GTA	13;13;13	G;T;A	13;12;13	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	120	porB1a	984	296	91.0	porB1a.l15.c4.ctg.1	1472	23.7	0	.	p	.	0	N237fs	FSHIFT	709	709	A	1260	1260	A	11	A	11	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	790	porB1b	1038	1038	99.42	porB1b.l6.c17.ctg.1	2099	110.2	0	.	p	.	0	I45V	NONSYN	133	135	ATT	647	649	GTT	170;169;170	G;T;T	151;153;156	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	790	porB1b	1038	1038	99.42	porB1b.l6.c17.ctg.1	2099	110.2	0	.	p	.	0	I75V	NONSYN	223	225	ATT	737	739	GTT	184;184;185	G;T;T	166;159;161	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	790	porB1b	1038	1038	99.42	porB1b.l6.c17.ctg.1	2099	110.2	0	.	p	.	0	S89T	NONSYN	265	267	AGC	779	781	ACC	194;194;193	A;C;C	165;167;169	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	790	porB1b	1038	1038	99.42	porB1b.l6.c17.ctg.1	2099	110.2	0	.	p	.	0	I98V	NONSYN	292	294	ATC	806	808	GTC	186;184;184	G;T;C	168;164;164	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	790	porB1b	1038	1038	99.42	porB1b.l6.c17.ctg.1	2099	110.2	0	.	p	.	0	S217G	NONSYN	649	651	AGT	1163	1165	GGT	168;168;167	G;G;T,C	154;150;151,1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	790	porB1b	1038	1038	99.42	porB1b.l6.c17.ctg.1	2099	110.2	1	SNP	p	G120K	1	.	.	358	360	AAG	872	874	AAG	176;179;179	A;A,C;G	159;162,1;163	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	790	porB1b	1038	1038	99.42	porB1b.l6.c17.ctg.1	2099	110.2	1	SNP	p	N121D	0	.	.	361	363	AAC	875	877	AAC	179;179;179	A;A;C	157;166;165	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	790	porB1b	1038	1038	99.42	porB1b.l6.c17.ctg.1	2099	110.2	1	SNP	p	A121N	1	.	.	361	363	AAC	875	877	AAC	179;179;179	A;A;C	157;166;165	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2200	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5447	121.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2271	2273	AAT	163;163;163	A;A;T,G	147;147;143,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	378	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1561	72.6	1	SNP	p	V57M	1	.	.	169	171	ATG	817	819	ATG	131;131;130	A;T;G	115;115;115	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
